Search
Dexamethasone Treatment Options
A collection of 1458 research studies where Dexamethasone is the interventional treatment. These studies are located in the United States. Dexamethasone is used for conditions such as Multiple Myeloma, Postoperative Pain and Lymphoma.
397 - 408 of 1458
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
High Dose Carfilzomib for Newly Diagnosed Myeloma
Completed
The purpose of this study is to test whether giving high doses of carfilzomib along with the other drugs (lenalidomide and dexamethasone) is safe and which dose is best tolerated by patients. In addition, the study is designed to test the amount of remaining myeloma cells in the body after treatment with higher carfilzomib doses which is known as minimal residual disease (MRD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/09/2024
Locations: Memorial Sloan Kettering Cancer Center, Basking Ridge, New Jersey +5 locations
Conditions: Multiple Myeloma
Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy
Active Not Recruiting
This phase 2 trial will test whether the combination of DaraRd (daratumumab + lenalidomide + dexamethasone) as induction therapy, followed by DRVd (daratumumab + lenalidomide + bortezomib + dexamethasone) consolidation therapy, if needed, will result in more patients achieving minimal residual disease (MRD)-negative status, relative to the standard of care. Consolidation therapy will be administered only to those patients with MRD-positive status after induction therapy.
This is a study based o... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/08/2024
Locations: University of Michigan Rogel Cancer Center, Ann Arbor, Michigan +3 locations
Conditions: Multiple Myeloma
2015-12: a Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
Active Not Recruiting
This study will assess whether adding one of the newest multiple myeloma therapies, daratumumab, into the Total Therapy approach helps patients live longer with fewer side effects
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/07/2024
Locations: University of Arkansas for Medical Sciences, Little Rock, Arkansas
Conditions: Multiple Myeloma
Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma
Active Not Recruiting
The goal of this clinical study is to learn more about the study drug, axicabtagene ciloleucel, in participants with relapsed or refractory large B-cell lymphoma (LBCL) in the outpatient setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California +15 locations
Conditions: Relapsed or Refractory Large B-cell Lymphoma
ON 123300 (Narazaciclib) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Recruiting
Multiple myeloma (MM) is a malignancy characterized by uncontrolled proliferation of plasma cells for which there is an urgent and unmet need to develop new, effective therapeutics. Onconova Therapeutics has developed a first-in-class oral inhibitor of CDK4 and ARK5 ON 123300 (NARAZACICLIB) which shows potent anti-myeloma activity in vitro and in vivo in preclinical models, and is undergoing evaluation in Phase 1-2 trials worldwide.
In this study, the researchers will test the safety and prelim... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/01/2024
Locations: Mount Sinai Health System, New York, New York
Conditions: Relapsed and/or Refractory Multiple Myeloma
Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases
Recruiting
To determine the safety and efficacy of using the drug azeliragon combined with stereotactic radiosurgery. Specifically, to determine if this combination will lead to improved response in the brain (tumor shrinking in size) and overall tumor control (how long tumor remains controlled).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/30/2024
Locations: Miami Cancer Institute at Baptist Health, Inc., Miami, Florida
Conditions: Cancer, Metastasis, Metastatic Cancer, Brain Metastases, Brain Metastases, Adult
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Active Not Recruiting
This is a Phase 3, randomized, open-label study designed to evaluate safety and efficacy of belantamab mafodotin in combination with bortezomib/dexamethasone (Arm A) versus daratumumab in combination with bortezomib/dexamethasone (Arm B) in the participants with relapsed recurrent multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/27/2024
Locations: GSK Investigational Site, Yuma, Arizona +143 locations
Conditions: Multiple Myeloma
A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)
Recruiting
The purpose of this study is to learn more about LP-118 (an experimental drug) and its side effects and decide on acceptable doses. The purpose of this study is to determine if LP-118 can be given safely with another medicine called ponatinib, that is FDA-approved for the treatment of acute lymphoblastic leukemia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/25/2024
Locations: University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois
Conditions: Acute Leukemia, Lymphoblastic Leukemia, Lymphoblastic Lymphoma
Selinexor, Daratumumab, Carfilzomib and Dexamethasone for the Treatment of High-Risk, Recurrent or Refractory Multiple Myeloma
Active Not Recruiting
This phase II trial studies the effect of selinexor when combined with carfilzomib, daratumumab, and dexamethasone in treating patients with high-risk multiple myeloma that has come back (recurrent) or has not responded to treatment (refractory) and who have received 1-3 prior lines of therapy. Selinexor may stop the growth of cancer cells by blocking a protein called CRM1 that is needed for cell growth. Carfilzomib is a type of drug called a proteasome inhibitor. A proteasome is a protein found... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/24/2024
Locations: Hackensack University Medical Center, Hackensack, New Jersey +3 locations
Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
Active Not Recruiting
This research study is evaluating a combination of three drugs called lenalidomide, subcutaneous (injection under the skin) bortezomib, and dexamethasone (RVD) as a possible treatment for multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/20/2024
Locations: Colorado Blood Cancer Institute, Denver, Colorado +7 locations
Conditions: Multiple Myeloma
Phase 1b Study Evaluating OPomD in Relapsed or Refractory Multiple Myeloma
Completed
A study evaluating two new formulations of oprozomib plus pomalidomide and dexamethasone in participants with relapsed refractory multiple myeloma.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
09/20/2024
Locations: Research Site, West Hollywood, California +19 locations
Conditions: Relapsed or Refractory Multiple Myeloma
Ridge Preservation With FDBA (Freeze Dried Bone Allograft) Using Dexamethasone vs. Saline
Recruiting
Following the removal of a tooth, a bone graft is often placed in the socket to try to maintain the volume of bone that was there when the tooth was present so that the bone does not "shrink". The bone graft is kept in place with a small piece of material over the top of the tooth socket and with stitches. This procedure is called "Ridge Preservation". Many different materials are used for ridge preservation, including bone allografts (bone grafts derived from a human tissue donor). These bone a... Read More
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
09/18/2024
Locations: UT Health Science Center at San Antonio, School of Dentistry, San Antonio, Texas
Conditions: Bone Graft, Tooth Extraction
397 - 408 of 1458